Komipharm International KRX:041960KOSDAQ
코미팜 · Korean news coverage and regulatory filings, organized.
Articles, 24h0
Articles, 7 days2
DART filings, 7 days1
Articles tracked6since Sep 11
In Q2 2026, Komipharm International reported revenue of ₩16.7bn, up 22.1% year on year, and operating profit of ₩1.6bn. Komipharm International (코미팜) appeared in 2 Korean news articles and 1 DART filing over the past seven days. Coverage peaked on Oct 28 with 2 articles. The most common catalyst was clinical & approvals (1). It was most often mentioned alongside 글로벌테크놀로지.
Filing signals Insider buying Screener
Komipharm International quarterly results consolidated, KRW
| Quarter | Revenue | YoY | Operating profit | Net income |
|---|---|---|---|---|
| Q2 2026 | ₩16.7bn | +22.1% | ₩1.6bn margin 9.8% | ₩518m |
| Q1 2026 | ₩11.9bn | -17.2% | ₩301m margin 2.5% | ₩689m |
| Q4 2025 derived | ₩11.9bn | -24.4% | −₩241m margin −2.0% | −₩4.3bn |
| Q3 2025 | ₩12.5bn | +13.6% | ₩66m margin 0.5% | −₩285m |
| Q2 2025 | ₩13.7bn | -28.6% | ₩1.6bn margin 11.9% | −₩3.3bn |
| Q1 2025 | ₩14.4bn | +11.7% | ₩509m margin 3.5% | −₩126m |
| Q4 2024 derived | ₩15.7bn | +37.0% | ₩376m margin 2.4% | ₩242m |
| Q3 2024 | ₩11.0bn | +40.2% | ₩897m margin 8.2% | ₩8.9bn |
Key accounts from quarterly, half-year and annual reports filed on DART. Q4 is derived as full-year minus nine-month figures. Figures may differ from preliminary earnings releases. Margin is operating profit divided by revenue — see operating margin.
Komipharm International top stories 2 weeks, by number of outlets
- 1
- 2
- 3
- 4
- 5